other
confidence high
sentiment neutral
materiality 0.60
Onconetix subsidiary Proteomedix licenses manufacturing IP for PancreaSure test to Immunovia
Onconetix, Inc.
- Proteomedix provides master cell lines and IP for three of five PancreaSure biomarkers.
- Immunovia pays $700K total: two $300K payments (Sep 2025, Mar 2026) plus $100K for materials.
- Immunovia to pay 3% royalty on net sales of PancreaSure from 2026 through 2032.
- Deal enables Immunovia to purchase reagents directly from Proteomedix's supplier.
- Onconetix remains focused on commercializing its own Proclarix prostate cancer test.
item 1.01item 7.01item 9.01
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.